Actualités

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best mid cap stocks to buy with highest upside potential. On May 22, ImmunityBio recently presented a health economic analysis at ISPOR 2026 demonstrating that ANKTIVA combined with BCG provides superior economic value compared to TAR-200 for patients with BCG-unresponsive non-muscle-invasive bladder cancer/NMIBC. Using a cost-consequence model based […]

In May 2026, ImmunityBio reported that the FDA accepted for review its supplemental Biologics License Application for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary disease, setting a PDUFA action date of January 6, 2027. The filing leans heavily on QUILT 3.032 data and an FDA-indicated focus on extrapolating results from CIS patients, which could materially broaden ANKTIVA’s approved bladder cancer population if the agency agrees. We’ll now...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best momentum stocks to buy according to analysts. ImmunityBio Inc. (NASDAQ:IBRX) announced on May 19 that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application for ANKTIVA® in combination with Bacillus Calmette-Guerin to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary […]

ImmunityBio presented its findings for ANKTIVA plus Bacillus Calmette-Guérin at the ISPOR 2026 conference.

ImmunityBio (IBRX) has been drawing attention after its lead product candidate Anktiva received FDA approval for use with BCG in certain bladder cancer patients, prompting investors to reassess the company’s broader immunotherapy pipeline and valuation. See our latest analysis for ImmunityBio. Since the FDA approval, ImmunityBio’s share price has cooled in the very short term, with 1-day and 7-day share price returns down 3% and 4.43%. However, the year-to-date share price return of 284.16%...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

ImmunityBio's shares rise after the FDA accepts a filing to expand Anktiva's use in bladder cancer, with a decision due by January 2027.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.

ImmunityBio Inc. on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory to develop, import, and commercialize the Tokyo strain of BCG for bladder cancer treatment in the U.S. ImmunityBio Secures Exclusive Rights To...

Stock Moves Higher Following Patent AnnouncementShares of ImmunityBio (NASDAQ:IBRX) gained 4. 5% in premarket trading on Monday after the company announced the issuance of five U.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t

Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The United States market remained flat over the last week, yet it has experienced a significant 28% rise over the past 12 months with earnings projected to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.

ImmunityBio received an FDA warning letter criticizing promotional claims for its lead product Anktiva. Following the warning letter, multiple class action lawsuits were filed alleging misleading statements and securities fraud. The issues center on whether the company accurately represented Anktiva's profile in marketing and investor communications. For investors tracking ImmunityBio (NasdaqGS:IBRX), this comes at a time when interest in the stock has been high, with a current share price...

IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.

Is IBRX a good stock to buy? We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s share was trading at $8.10 as of April 21st. ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and […]

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026. Product revenue in the quarter was up 168% year over year to $44.2 million. The increase […]

ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ImmunityBio has now commercially launched its immunotherapy ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications, with distribution supported by regional partners Biopharma and Cigalah Healthcare and its local subsidiary. This marks one of the first commercial rollouts of ANKTIVA for both bladder and lung cancer in the Middle East and North Africa, a region facing a rapidly growing cancer burden and rising demand for additional treatment...

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best biotech stocks on our list. TheFly reported on April 21 that ImmunityBio, Inc. (NASDAQ:IBRX) announced that its immunotherapy ANKTIVA has begun commercial availability in Saudi Arabia, with initial patients already identified for treatment. […]

ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the stock during the recent lightning round, Cramer said: You know there’s a lot of dispute about what they did. And I’m going to tell you that it is not clear exactly what they did wrong, but […]